SCHEMBL6486330

SCHEMBL6486330

COc1ccc(Cl)cc1-c1ccc(C(C)=CC(=O)O)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
HPGD P15428 2/20 0.50
ERN1 O75460 1/20 0.48
LTB4R Q15722 1/20 0.46
MME P08473 1/20 0.45
MMEL1 Q495T6 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TTR P02766 1/20 0.44
PTGDR2 Q9Y5Y4 2/20 0.43
SLC9A1 P19634 2/20 0.42
MAPT P10636 1/20 0.41
CTSA P10619 2/20 0.41
NR4A1 P22736 1/20 0.41
NR4A2 P43354 1/20 0.41
NR4A3 Q92570 1/20 0.41
PTGER1 P34995 1/20 0.41
ADRB2 P07550 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6486328 1.00 ALDH1A1 (0.50) ALDH1A1HPGDERN1LTB4RMME
SCHEMBL6493632 0.85 MAPT (0.49) ALDH1A1HPGDLTB4RMAPT
SCHEMBL6493546 0.85 MAPT (0.49) ALDH1A1HPGDLTB4RMAPT
SCHEMBL6492644 0.81 ERN1 (0.47) ALDH1A1HPGDERN1MMEMMEL1
SCHEMBL6492649 0.81 ERN1 (0.47) ALDH1A1HPGDERN1MMEMMEL1
SCHEMBL6492648 0.81 ERN1 (0.47) ALDH1A1HPGDERN1MMEMMEL1
SCHEMBL11540793 0.81 SRD5A2 (0.60) MAPTNR4A1NR4A2NR4A3
SCHEMBL11540788 0.81 SRD5A2 (0.60) MAPTNR4A1NR4A2NR4A3
SCHEMBL30791351 0.77 MRGPRX4 (0.58) ALDH1A1HPGDTTRMAPT
SCHEMBL5944267 0.77 HDAC8 (0.61) ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6867218-B2 Compounds, their preparation and use NOVO NORDISK A/S (DK) 2005-03-15 US disclosed
US-20030195200-A1 Compounds, their preparation and use VTVX HOLDINGS II LLC 2003-10-16 US disclosed
US-6555577-B1 For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
EP-1254101-A1 PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY Novo Nordisk A/S (DK) 2002-11-06 EP disclosed
WO-2001055085-A1 PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY NOVO NORDISK A/S (DK) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195200-A1 Compounds, their preparation and use PPARG, PPARA, PPARD ALDH1A1 257/4885HPGD 292/4885ERN1 1741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.